Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Helena A. Yu, MD"'
Autor:
Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100607- (2023)
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such
Externí odkaz:
https://doaj.org/article/eb50687c81bc4fa09768c4beb4a3d785
Autor:
A.J. Piper-Vallillo, MD, Julia K. Rotow, MD, Jacqueline V. Aredo, MD, Khvaramze Shaverdashvili, MD, PhD, Jia Luo, MD, Jennifer W. Carlisle, MD, Hatim Husain, MD, Alona Muzikansky, MA, Rebecca S. Heist, MD, Deepa Rangachari, MD, Suresh S. Ramalingam, MD, Heather A. Wakelee, MD, Helena A. Yu, MD, Lecia V. Sequist, MD, Joshua M. Bauml, MD, Joel W. Neal, MD, PhD, Zofia Piotrowska, MD, MHS
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100328- (2022)
Introduction: This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in EGFR-mutant NSCLC. Methods: Retrospective review identified 105 pat
Externí odkaz:
https://doaj.org/article/a0defd29b0c2448591b1a44036d37442
Autor:
Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256- (2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Externí odkaz:
https://doaj.org/article/08ab67b4ab914fc8921cb36a60feebfe